Current status of novel agents in advanced gastroesophageal adenocarcinoma. - Wikidata - awgldk - TriplyDB

Current status of novel agents in advanced gastroesophageal adenocarcinoma.

Current status of novel agents in advanced gastroesophageal adenocarcinoma.

http://www.wikidata.org/entity/Q34962039

about

New advances in targeted gastric cancer treatment Emerging therapeutic targets in esophageal adenocarcinoma Fibroblast growth factor receptor signaling as therapeutic targets in gastric cancer Advanced gastric cancer: What we know and what we still have to learn Trastuzumab-Based Photoimmunotherapy Integrated with Viral HER2 Transduction Inhibits Peritoneally Disseminated HER2-Negative Cancer.Salinomycin exerts anti-angiogenic and anti-tumorigenic activities by inhibiting vascular endothelial growth factor receptor 2-mediated angiogenesis.Expression of Mismatch Repair Proteins in Early and Advanced Gastric Cancer in Poland.Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine Overexpression of CHD1L is associated with poor survival and aggressive tumor biology in esophageal carcinoma.Phase I dose-escalation trial of Sym004, an anti-EGFR antibody mixture, in Japanese patients with advanced solid tumors

P2860

Q26738548-F73C85D1-1DF3-4FF9-A599-8823FBE754C5 Q26751209-19827632-A9B3-4ABE-9D53-CAD53F4DC0C1 Q26764932-06FE37B5-41E5-4560-8FC3-AD724B1079A4 Q26774528-1B020C1B-F179-42D1-87FE-840DE2A7AC60 Q30724810-499EAF4F-041D-443E-8CB7-A0E9717086D2 Q35983858-319F6132-44D0-4692-9017-AC67657E02A9 Q37200235-C5CE41D5-95F0-4EC2-9D4F-F8E14A0C6DB8 Q38881033-D7601D26-CCF5-43B0-875A-DE91FD9C3797 Q47098880-BC015750-6EB7-4B03-B11A-0F0E05A9C7D8 Q57652734-54A2613F-D5F9-4F36-989B-6A5F9B510E1B

P2860

Current status of novel agents in advanced gastroesophageal adenocarcinoma.

http://www.wikidata.org/entity/Q34962039

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Current status of novel agents in advanced gastroesophageal adenocarcinoma.

@ast

Current status of novel agents in advanced gastroesophageal adenocarcinoma.

@en

Current status of novel agents in advanced gastroesophageal adenocarcinoma.

@nl

type

label

Current status of novel agents in advanced gastroesophageal adenocarcinoma.

@ast

Current status of novel agents in advanced gastroesophageal adenocarcinoma.

@en

Current status of novel agents in advanced gastroesophageal adenocarcinoma.

@nl

prefLabel

Current status of novel agents in advanced gastroesophageal adenocarcinoma.

@ast

Current status of novel agents in advanced gastroesophageal adenocarcinoma.

@en

Current status of novel agents in advanced gastroesophageal adenocarcinoma.

@nl

P1433

Q34962039-77580CBA-65D0-4C4C-80F7-C1630E99366B

P1476

Q34962039-B3C840F0-6A13-4802-9F47-8526AEAA4B92

P2093

Q34962039-9370E536-7DC8-4CFA-AE9E-99412112AA8C

Q34962039-96770BE1-077D-4235-880E-29820D0024E4

P2860

Q34962039-04A2D737-A0D4-49A0-AFE9-BFFFABCB61E7

Q34962039-0A23EFF4-B03C-425F-92B1-518228627438

Q34962039-0B0281CB-BEDC-46D3-A3A3-DBA6F2B9BC6F

Q34962039-0D20CC6F-BB27-42F4-9656-6BB9A0E29B36

Q34962039-116DDA1E-6DF9-4FEF-9F0C-471B7D2187B1

Q34962039-11924B51-0095-4CFB-BD63-AEF68834EF0D

Q34962039-15935CC7-168A-479A-B709-9414869179D2

Q34962039-15BE5E4D-3297-458D-AE6A-D67BE88997DD

Q34962039-15BFA1B3-2F3C-4B6A-A0EB-B93257DB97B6

Q34962039-17E26286-5F04-450D-8754-4F831F41E72E

P304

Q34962039-789A48BE-E132-42C7-8F64-F6F88CCF6556

P31

Q34962039-B4503125-00C8-45D0-B4CD-725536E65241

P356

Q34962039-F52AE4AB-CAFE-4A63-81C5-BD7F2E30121C

P433

Q34962039-3054735B-EA1F-4962-BB84-5AE5A2076854

P478

Q34962039-081AE2B9-4869-433B-99DC-EAF2FB078EBC

P577

Q34962039-6573DDF2-76C5-4377-819B-64FD639507BD

P698

Q34962039-E04D4E9B-6612-4587-BAB0-BE3AB5935FAB

P921

Q34962039-21384C89-EDAA-45E7-8A19-308358F053BE

P932

Q34962039-81B1B762-F41C-4540-B2FA-EB8AAF280E1B

P356

J.ISSN.2078-6891.2014.098

P1433

Journal of gastrointestinal oncology

P1476

Current status of novel agents in advanced gastroesophageal adenocarcinoma.

@en

P2093

Khaldoun Almhanna

http://www.w3.org/2001/XMLSchema#string

Nishi Kothari

http://www.w3.org/2001/XMLSchema#string

P2860

A comprehensive pathway map of epidermal growth factor receptor signaling

Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

P304

60-74

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3978/J.ISSN.2078-6891.2014.098

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25642339

http://www.w3.org/2001/XMLSchema#string

P921

P932

4294823

http://www.w3.org/2001/XMLSchema#string